Literature DB >> 10592940

Toxicokinetics and oral bioavailability of fumonisin B1.

M R Martinez-Larranaga1, A Anadon, M J Diaz, M L Fernandez-Cruz, M A Martinez, M T Frejo, M Martinez, R Fernandez, R M Anton, M E Morales, M Tafur.   

Abstract

The kinetics of fumonisin B1 (FB1) after single doses of 10 mg FB1/kg (po) or 2 mg FB1/kg (i.v.) were studied in male Wistar rats. Serial blood samples were obtained after p.o and i.v. administration. Liver and kidney tissue samples were also obtained after p.o administration. Plasma, liver and kidney concentrations of FB1 were determined by a reversed-phase high-performance liquid chromatographic assay using precolumn 0-phthaldialdehyde derivatisation with fluorescence detection. The FB1 plasma profile could be adequately described by a 2-compartment open model. For FB1, the elimination half-life from plasma was 1.03 h after i.v. and 3.15 h after p.o administration. The apparent volume of distribution and volume of distribution at steady state for FB1 were 0.11 and 0.072 L, respectively, after i.v. administration. The total plasma clearance of FB1 was the same for both the p.o and i.v. routes, 0.072 L/h. After the single p.o dose, FB1 was rapidly absorbed with a Tmax of 1.02 h. The maximum plasma concentration of FB1 was 0.18 microgram/mL. The p.o bioavailability of FB1 was 3.5%. The tissue concentration time data for FB1 fit a 1-compartment open model. Considerable concentrations of FB1 were found in the liver and kidney tissues. The elimination half-lives for FB1 were longer for liver (4.07 h) and kidney (7.07 h) than for plasma (3.15 h). Tissue accumulation of FB1 was evidenced by the tissue/plasma area under the concentration-time curve (AUC) ratios; the AUCtissue/AUCplasma for FB1 was 2.03 in liver and 29.89 in kidney.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10592940

Source DB:  PubMed          Journal:  Vet Hum Toxicol        ISSN: 0145-6296


  11 in total

1.  Immunobiological effects of fumonisin B1 in experimental subchronic mycotoxicoses in rats.

Authors:  M G Theumer; A G López; D T Masih; S N Chulze; Hector R Rubinstein
Journal:  Clin Diagn Lab Immunol       Date:  2002-01

2.  The discovery of novel predictive biomarkers and early-stage pathophysiology for the transition from gestational diabetes to type 2 diabetes.

Authors:  Saifur R Khan; Haneesha Mohan; Ying Liu; Battsetseg Batchuluun; Himaben Gohil; Dana Al Rijjal; Yousef Manialawy; Brian J Cox; Erica P Gunderson; Michael B Wheeler
Journal:  Diabetologia       Date:  2019-01-15       Impact factor: 10.122

3.  Calcium montmorillonite clay reduces AFB1 and FB1 biomarkers in rats exposed to single and co-exposures of aflatoxin and fumonisin.

Authors:  Nicole J Mitchell; Kathy S Xue; Shuhan Lin; Alicia Marroquin-Cardona; Kristal A Brown; Sarah E Elmore; Lili Tang; Amelia Romoser; Wentzel C A Gelderblom; Jia-Sheng Wang; Timothy D Phillips
Journal:  J Appl Toxicol       Date:  2013-11-06       Impact factor: 3.446

4.  Validation of fumonisin biomarkers in F344 rats.

Authors:  Qingsong Cai; Lili Tang; Jia-Sheng Wang
Journal:  Toxicol Appl Pharmacol       Date:  2007-08-16       Impact factor: 4.219

5.  In vivo formation of N-acyl-fumonisin B1.

Authors:  Henning Harrer; Hans Ulrich Humpf; Kenneth A Voss
Journal:  Mycotoxin Res       Date:  2014-10-19       Impact factor: 3.833

6.  Chronic exposure to deoxynivalenol has no influence on the oral bioavailability of fumonisin B1 in broiler chickens.

Authors:  Gunther Antonissen; Mathias Devreese; Filip Van Immerseel; Siegrid De Baere; Sabine Hessenberger; An Martel; Siska Croubels
Journal:  Toxins (Basel)       Date:  2015-02-16       Impact factor: 4.546

7.  Oral and Intravenous Fumonisin Exposure in Pigs-A Single-Dose Treatment Experiment Evaluating Toxicokinetics and Detoxification.

Authors:  Hanna Schertz; Jeannette Kluess; Jana Frahm; Dian Schatzmayr; Ilse Dohnal; Gerlinde Bichl; Heidi Schwartz-Zimmermann; Gerhard Breves; Sven Dänicke
Journal:  Toxins (Basel)       Date:  2018-04-05       Impact factor: 4.546

8.  Dose and Exposure Time-Dependent Renal and Hepatic Effects of Intraperitoneally Administered Fumonisin B₁ in Rats.

Authors:  András Szabó; Judit Szabó-Fodor; Mariam Kachlek; Miklós Mézes; Krisztián Balogh; Róbert Glávits; Omeralfaroug Ali; Yarsmin Yunus Zeebone; Melinda Kovács
Journal:  Toxins (Basel)       Date:  2018-11-09       Impact factor: 4.546

9.  Evaluation of sphingolipids in Wistar rats treated to prolonged and single oral doses of fumonisin b₁.

Authors:  Glória M Direito; Adriana P Almeida; Simone Aquino; Tatiana Alves Dos Reis; Claudia Rodrigues Pozzi; Benedito Corrêa
Journal:  Int J Mol Sci       Date:  2008-12-27       Impact factor: 6.208

10.  Fumonisin B₁ (FB₁) Induces Lamellar Separation and Alters Sphingolipid Metabolism of In Vitro Cultured Hoof Explants.

Authors:  Nicole Reisinger; Ilse Dohnal; Veronika Nagl; Simone Schaumberger; Gerd Schatzmayr; Elisabeth Mayer
Journal:  Toxins (Basel)       Date:  2016-03-24       Impact factor: 4.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.